Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis
CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS
Approximately 21 subjects with amyotrophic lateral sclerosis (ALS) will be randomized (6 to 1) to receive by mouth seven morning doses of CC100 or placebo for 7 days.
- Trial name
- CC100B (NCT03049046)
- Testing
- CC100
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Chemigen, LLC
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical…
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy 4
- Trial name
- NCT06300996
- Testing
- Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Marco Capogrosso
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how…
- Trial name
- NCT07883590
- Testing
- LY3873862, CYP450 Drug Cocktail
- Where
- 4 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Amyotrophic Lateral Sclerosis (ALS)
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]
This is a single-center, phase 2 randomized clinical trial of tamoxifen on mean percent predicted isometric muscle strength in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00214110
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Wisconsin, Madison
Muscular Atrophy, Spinal
Adult Spinal Muscular Atrophy (SMA) China Registry
The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA).
- Trial name
- NCT05618379
- Where
- 12 sites in China
- Volunteers
- 200 people
- Sponsor
- Biogen
ALS (Amyotrophic Lateral Sclerosis)
A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a study of transplantation of Astrocytes derived from human embryonic stem cells, in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03482050
- Testing
- AstroRx
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Kadimastem
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease.
- Trial name
- AMSC-ALS-001 (NCT03828123)
- Testing
- Suspension of human autologous MSC 3P in 1.5 ml
- Volunteers
- 26 people
- Sponsor
- Bioinova, s.r.o.
Spinal Muscular Atrophy (SMA)
An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With Spinal Muscular Atrophy Compared With Healthy Controls: Active-NBS Study (UK)
Active-NBS is a study to evaluate the muscle development of patients with spinal muscular atrophy (SMA) who are diagnosed at birth. Medicines have become available in the last decade, and many patients are treated very early.
- Trial name
- Active-NBS UK (NCT07543003)
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Amyotrophic Lateral Sclerosis
QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up
Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients.
- Trial name
- PEM-SLA (NCT06284161)
- Testing
- Quadriceps Combined Test
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Spinal Muscular Atrophy
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
- Trial name
- SYNAPSE-SMA (NCT05794139)
- Testing
- NMD670
- Where
- 25 sites in United States, Belgium and 6 more
- Volunteers
- 52 people
- Sponsor
- NMD Pharma A/S
Spinal Muscular Atrophy
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)
The primary objective is to examine the clinical efficacy of multiple doses of nusinersen (ISIS 396443) administered intrathecally to participants with Infantile-Onset Spinal Muscular Atrophy (SMA).
- Trial name
- NCT01839656
- Testing
- nusinersen
- Where
- 4 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Biogen
Muscular Atrophy, Spinal, Type II, Muscular Atrophy, Spinal, Type III
Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study
There is no complete cure for SMA yet. However, the discovery of the genetic cause of SMA has led to the development of several treatment options that affect the genes involved in SMA - a gene replacement therapy called…
- Trial name
- SMA-AtHome (NCT05839145)
- Testing
- Strength force measurment, Time tests, Motor scales
- Where
- 6 sites in France
- Sponsor
- Institut de Myologie, France
Amyotrophic Lateral Sclerosis
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
- Trial name
- NCT04768972
- Testing
- ION363
- Where
- 25 sites in United States, Belgium and 14 more
- Volunteers
- 89 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Muscular Atrophy, Spinal
A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
In this study, researchers will learn more about the effects of nusinersen, also known as Spinraza®, in Korean participants with spinal muscular atrophy, also known as SMA.
- Trial name
- STANDARD (NCT04317794)
- Testing
- Nusinersen Sodium Injection
- Where
- 16 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood.
- Trial name
- NCT06656702
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 2)
The research is aimed to asses the validity of the communication system improving the quality of life and the degree of sanctification of clinical patients and their caregiver.
- Trial name
- NCT03806634
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Amyotrophic Lateral Sclerosis
Safety and Efficacy of Intravenous Administration of SHED-CM for ALS
This study evaluates the safety and efficacy of Stem Cell from Human Exfoliated Deciduous teeth Conditioned Media (SHED-CM) in patients with Amyotrophic Lateral Sclerosis (ALS), using the Japanese version of the revised ALS…
- Trial name
- SCA202401 (NCT06889857)
- Testing
- The study drug is SHED-CM manufactured by U-Factor
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Hitonowa Medical
Spinal Muscular Atrophy
Spinal Muscular Atrophy on Wheels, Using Power Mobility
The group of children diagnosed with Spinal Muscular Atrophy (SMA) has serious restrictions on participation. SMA is a neuromuscular disease that leads to neuromusculoskeletal disorders that limit functional activities, sometimes…
- Trial name
- SMAPmob (NCT05589987)
- Testing
- power mobility
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- University of Castilla-La Mancha
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis, Sporadic
Dual Treatment With Lithium and Valproate in ALS.
This is a pilot study in 40 subjects with definite ALS to evaluate the efficacy of valproate and lithium carbonate. After a random assignation of the dual treatment vs.
- Trial name
- NCT03204500
- Testing
- Active treatment with dual therapy
- Where
- Mexico
- Volunteers
- 43 people
- Sponsor
- El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
OBJECTIVES: I. Evaluate the effects of androgen suppression with leuprolide and androgen replacement with testosterone enanthate on muscle strength in men with Kennedy's disease or other motor neuron disease.
- Conditions
- Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis, Spinobulbar Muscular Atrophy
- Trial name
- NCT00004771
- Testing
- leuprolide, testosterone
- Volunteers
- 40 people
- Sponsor
- National Center for Research Resources (NCRR)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.